G-1 (CAS 881639-98-1): Selective GPR30 Agonist for Targeted Signaling and Disease Modulation

Introduction: Beyond Classical Estrogen Receptor Pathways

The rapid, non-genomic actions of estrogen have reshaped our understanding of hormone signaling in health and disease. While classical nuclear estrogen receptors ERα and ERβ have been extensively studied, it is now clear that the G protein-coupled estrogen receptor (GPR30/GPER1) mediates distinct, rapid signaling events that are fundamentally different from nuclear receptor pathways. G-1 (CAS 881639-98-1), available from APExBIO (SKU: B5455), represents a breakthrough tool for dissecting these mechanisms with unprecedented selectivity and potency. This article offers a comprehensive, mechanistically rich overview of G-1 as a selective GPR30 agonist, with a focus on its unique applications in cardiovascular, cancer, and immunological research—delving deeper into advanced experimental design and translational implications than previous resources.

G-1: Molecular Characteristics and Selectivity Profile

G-1 is a crystalline compound (C₂₁H₁₈BrNO₃; MW 412.28) engineered for high-affinity binding to GPR30 (Ki ≈ 11 nM), with negligible activity at ERα or ERβ even at micromolar concentrations. This strict selectivity is essential for isolating GPR30-mediated effects, minimizing confounding activation of nuclear pathways. G-1 is highly soluble in DMSO (≥41.2 mg/mL), but insoluble in water and ethanol, facilitating the preparation of concentrated stock solutions for in vitro and in vivo use.

Mechanism of Action: Deciphering GPR30-Mediated Signaling

Distinct Signaling Pathways: Calcium and PI3K

Upon binding, G-1 activates GPR30 primarily localized to the endoplasmic reticulum. This triggers:

• Intracellular calcium signaling via GPR30: G-1 elevates intracellular calcium with an EC₅₀ of 2 nM, initiating rapid downstream effects distinct from classical genomic estrogen responses.
• GPR30-mediated PI3K signaling pathway: Activation leads to nuclear accumulation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), modulating key cellular responses such as proliferation, migration, and survival.

This mechanistic profile uniquely positions G-1 as the gold standard for probing non-classical estrogen signaling. Notably, a seminal study demonstrated that GPR30 activation by G-1, alongside ERα activation, was critical for the normalization of immune responses following hemorrhagic shock, emphasizing its translational relevance (Wang et al., 2021).

Comparative Analysis: G-1 Versus Alternative GPR30 Modulators

Existing approaches to studying rapid estrogen signaling have relied on natural ligands (e.g., 17β-estradiol), ERα- and ERβ-selective compounds, or less selective GPR30 agonists. However, these agents often lack the specificity required to unambiguously attribute observed effects to GPR30. G-1, by contrast, offers:

• Superior selectivity (no significant ERα/ERβ activation even at high concentrations)
• Nanomolar potency (Ki ≈ 11 nM, functional effects in sub-nanomolar to low nanomolar range)
• Consistent performance in both in vitro and in vivo models

This positions G-1 as the agent of choice for mechanistic and translational studies where receptor specificity is paramount. Previous reviews—such as Redefining Rapid Estrogen Signaling: Strategic Frontiers—have provided broad overviews of G-1’s role in translational research. In contrast, this article focuses on advanced mechanistic dissection and methodological strategies, enabling researchers to design experiments with enhanced precision.

Applications in Cardiovascular Research: GPR30 Activation and Disease Modification

G-1 in Heart Failure and Cardiac Fibrosis Attenuation

Cardiovascular diseases, particularly heart failure and cardiac fibrosis, are characterized by maladaptive remodeling and impaired contractility. Chronic administration of G-1 in preclinical models (e.g., female Sprague-Dawley rats with bilateral ovariectomy and induced heart failure) has demonstrated:

• Reduction in brain natriuretic peptide (BNP) levels
• Suppression of cardiac fibrosis
• Improved cardiac contractility
• Regulation of adrenergic receptor expression: normalization of β₁-adrenergic and upregulation of β₂-adrenergic receptors

This cardioprotective effect is mediated through GPR30-dependent signaling cascades and not via classic nuclear ERs, allowing for therapeutic targeting of rapid estrogenic effects without the side effects associated with genomic estrogen signaling. For researchers interested in the intersection of GPR30 activation in cardiovascular research and translational modeling, our analysis builds upon, but extends beyond, the summary in Strategic Frontiers in GPR30 Activation by offering detailed methodological considerations and highlighting experimental nuances.

Experimental Design Considerations

Optimal use of G-1 in cardiac models involves:

• Preparation of DMSO stock solutions (>10 mM), with warming and ultrasonication for complete dissolution
• Short-term storage at -20°C to preserve activity; avoid repeated freeze-thaw cycles
• Careful dosing regimens to distinguish acute versus chronic GPR30 effects
• Parallel use of ERα/ERβ antagonists to confirm GPR30 specificity

Advanced Applications in Cancer Biology: Inhibition of Breast Cancer Cell Migration

Mechanistic Insights into GPR30-Mediated Migration Inhibition

G-1’s ability to inhibit migration in breast cancer cell lines (SKBr3, MCF7) at sub-nanomolar IC₅₀ values (0.7 nM and 1.6 nM, respectively) highlights its utility in dissecting estrogen-driven tumor biology. Importantly, these anti-migratory effects are achieved without activating ERα/ERβ, making G-1 indispensable for deconvoluting the contributions of rapid, non-genomic estrogen signaling to cancer progression.

While Translating Rapid Estrogen Signaling: Strategic Opportunities contextualizes G-1’s impact in translational oncology, this article delves deeper into signaling mechanisms—focusing on the integration of calcium and PI3K pathways, and their crosstalk with cytoskeletal remodeling and cell motility.

Strategic Use in Breast Cancer Research

Researchers can leverage G-1 to:

• Dissect GPR30-specific contributions to metastatic potential
• Probe the role of calcium and PIP3 in cytoskeletal dynamics
• Develop combinatorial strategies that target both genomic and non-genomic estrogen pathways

This enables more precise modeling of tumor microenvironment interactions and identification of novel therapeutic targets.

Integration with Immunological Models: GPR30 in Immune Homeostasis

Recent work has illuminated the role of GPR30 in immune modulation. In a pivotal study by Wang et al. (2021), G-1 was shown to restore splenic CD4⁺ T lymphocyte proliferation and cytokine production following hemorrhagic shock—effects attributed to the inhibition of endoplasmic reticulum stress (ERS) via GPR30 and ERα activation. G-1’s ability to normalize immune responses, even after severe trauma, highlights its value for immunometabolic research and for understanding the gender dimorphism observed in post-injury immune recovery.

Unlike more generalist reviews such as G-1 (CAS 881639-98-1): Selective GPR30 Agonist for Rapid Estrogen Signaling, which focus on broad experimental parameters, this article provides an in-depth mechanistic rationale for the use of G-1 in immune normalization and ERS modulation, enabling experimentalists to design highly specific models for trauma, sepsis, and beyond.

Methodological Considerations: Maximizing Experimental Rigor

• Solvent selection: Use DMSO exclusively; avoid water and ethanol.
• Stock solution preparation: Dissolve at >10 mM, apply heat and sonication as needed.
• Storage: Short-term at -20°C; do not store long-term or repeatedly freeze-thaw.
• Controls: Always include ER antagonists and GPR30 inhibitors to confirm specificity.
• Readout selection: Employ both rapid (e.g., calcium flux, PIP3 accumulation) and long-term (e.g., fibrosis, migration assays) endpoints.

These considerations ensure that results obtained with G-1 reflect true GPR30-dependent processes, enhancing reproducibility and translational value.

Conclusion and Future Outlook: G-1 as a Platform for Precision Endocrine Research

G-1 (CAS 881639-98-1) has emerged as the definitive tool for investigating G protein-coupled estrogen receptor agonist signaling across cardiovascular, cancer, and immune models. Its unparalleled selectivity, nanomolar potency, and robust in vitro/in vivo applicability make it indispensable for researchers aiming to elucidate GPR30-specific mechanisms. By building on—but moving beyond—the perspectives offered in articles such as Precision Targeting of GPR30 in Immunometabolic Regulation, this resource provides advanced guidance for experimental rigor and translational relevance.

As the field moves toward precision endocrinology and targeted therapeutics, G-1 will remain central to the development of next-generation models and interventions. For those seeking a potent, selective, and validated GPR30 agonist, G-1 (CAS 881639-98-1) from APExBIO sets the standard for scientific discovery and innovation.